Literature DB >> 2401124

Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one.

G J Kontoghiorghes1, J G Goddard, A N Bartlett, L Sheppard.   

Abstract

Pharmacokinetic studies have been carried out with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). HPLC analysis of serum of a normal volunteer and seven transfusional iron loaded patients who ingested a 3 gm dose of L1 revealed that L1 was most probably absorbed from the stomach and was transferred to the blood with a half-life of 0.7 to 32 minutes. L1 reached maximum concentration in the serum 12 to 120 minutes after administration with 85% to 90% elimination within the first 5 to 6 hours, with a half-life of 47 to 134 minutes. L1 and its glucuronide metabolite were identified in serum and urine but not in feces. In most cases hydrolysis of 24-hour urine samples with use of beta-glucuronidase resulted in almost complete recovery of the administered dose. Urinary iron excretion was proportional to the iron load but not to the serum or urine concentration of L1. The therapeutic efficiency of L1 can therefore be improved by repeated administration of 2 to 3 gm doses at least every 6 hours.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2401124     DOI: 10.1038/clpt.1990.147

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  25 in total

1.  Oral iron chelation is here.

Authors:  G J Kontoghiorghes
Journal:  BMJ       Date:  1991-11-23

2.  Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.

Authors:  Patricia Evans; Reem Kayyali; Robert C Hider; John Eccleston; John B Porter
Journal:  Transl Res       Date:  2010-05-27       Impact factor: 7.012

3.  Pharmaceutical analysis of the oral iron chelator deferiprone (DMHP,L1).

Authors:  R Lange; W Lameijer; C Slijkhuis; D de Kaste
Journal:  Pharm World Sci       Date:  1996-08

4.  Inhibition of prostate cancer proliferation by Deferiprone.

Authors:  Rui V Simões; Suresh Veeraperumal; Inna S Serganova; Natalia Kruchevsky; Joseph Varshavsky; Ronald G Blasberg; Ellen Ackerstaff; Jason A Koutcher
Journal:  NMR Biomed       Date:  2017-03-08       Impact factor: 4.044

Review 5.  Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.

Authors:  J A Barman Balfour; R H Foster
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

6.  New developments and controversies in iron metabolism and iron chelation therapy.

Authors:  Christina N Kontoghiorghe; George J Kontoghiorghes
Journal:  World J Methodol       Date:  2016-03-26

Review 7.  Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases.

Authors:  G J Kontoghiorghes
Journal:  Indian J Pediatr       Date:  1993 Jul-Aug       Impact factor: 1.967

Review 8.  Oral iron chelation: a review with special emphasis on Indian work on deferiprone (L1).

Authors:  M B Agarwal
Journal:  Indian J Pediatr       Date:  1993 Jul-Aug       Impact factor: 1.967

Review 9.  Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.

Authors:  George J Kontoghiorghes; Katia Neocleous; Annita Kolnagou
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

10.  Inhibition of HIV-1 gene expression by Ciclopirox and Deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5A.

Authors:  Mainul Hoque; Hartmut M Hanauske-Abel; Paul Palumbo; Deepti Saxena; Darlene D'Alliessi Gandolfi; Myung Hee Park; Tsafi Pe'ery; Michael B Mathews
Journal:  Retrovirology       Date:  2009-10-13       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.